In vivo dosimetry based on SPECT and MR imaging of 166Ho- microspheres for treatment of liver malignancies

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2093-2100

  Smits, Maarten L J ^a   Elschot, Mattijs ^a   Van Den Bosch, Maurice A A J ^a   Van De Maat, Gerrit H ^b   Van Het Schip, Alfred D ^a   Zonnenberg, Bernard A ^a   Seevinck, Peter R ^b   Verkooijen, Helena M ^a   Bakker, Chris J ^b   De Jong, Hugo W A M ^a   Lam, Marnix G E H ^a   Nijsen, Johannes F W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Holmium; MRI; Radioembolization; SIRT; SPECT

Indexed keywords

HOLMIUM 166; MICROSPHERE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; HOLMIUM; LACTIC ACID; POLYLACTIC ACID; POLYMER;

ADULT; AGED; ARTICLE; CANCER RADIOEMBOLIZATION; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; FEMALE; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; INTERMETHOD COMPARISON; LIVER CANCER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; VERY ELDERLY; ARTIFICIAL EMBOLISM; CHEMISTRY; LIVER; LIVER TUMOR; MIDDLE AGED; MULTIMODAL IMAGING; PHASE 1 CLINICAL TRIAL; RADIATION EXPOSURE; RADIOEMBOLIZATION; RADIOMETRY; SAFETY; SCINTISCANNING; SIRT; LIVER NEOPLASMS; RADIATION RESPONSE;

HOLMIUM; MRI; RADIOEMBOLIZATION; SIRT; SPECT;

ADULT; AGED; AGED, 80 AND OVER; EMBOLIZATION, THERAPEUTIC; FEMALE; HOLMIUM; HUMANS; LACTIC ACID; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; MIDDLE AGED; MULTIMODAL IMAGING; POLYMERS; RADIOMETRY; SAFETY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84893421780     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119768     Document Type: Article

References (34)

1. Bierman HR, Byron RL Jr, Kelley KH, Grady A. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst. 1951;12:107-131.
2. Elschot M, Nijsen JF, Dam AJ, de Jong HW. Quantitative evaluation of scintillation camera imaging characteristics of isotopes used in liver radioembolization. PLoS ONE. 2011;6:e26174.
3. Garin E, Lenoir L, Rolland Y, et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-263.
4. Walrand S, Flux GD, Konijnenberg MW, et al. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur J Nucl Med Mol Imaging. 2011;38(suppl 1):S57-S68.
5. Rong X, Du Y, Ljungberg M, Rault E, Vandenberghe S, Frey EC. Development and evaluation of an improved quantitative 90Y bremsstrahlung SPECT method. Med Phys. 2012;39:2346-2358.
6. de Wit TC, Xiao J, Nijsen JF, et al. Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol. 2006;51:4773-4787.
7. Nijsen JF, Seppenwoolde JH, Havenith T, Bos C, Bakker CJ, van het Schip AD. Liver tumors: MR imaging of radioactive holmium microspheres-phantom and rabbit study. Radiology. 2004;231:491-499.
8. Seevinck PR, van de Maat GH, de Wit TC, Vente MA, Nijsen JF, Bakker CJ. Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization. Int J Radiat Oncol Biol Phys. 2012;83:e437-e444.
9. Vente MA, Nijsen JF, de Wit TC, et al. Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging. 2008;35:1259-1271.
10. Seevinck PR, Seppenwoolde JH, de Wit TC, et al. Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem. 2007;7:317-334.
11. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012;13:1025-1034.
12. Zielhuis SW, Nijsen JF, de Roos R, et al. Production of GMP-grade radioactive holmium loaded poly(L-lactic acid) microspheres for clinical application. Int J Pharm. 2006;311:69-74.
13. Nijsen JF, Zonnenberg BA, Woittiez JR, et al. Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med. 1999;26:699-704.
14. Smits ML, Nijsen JF, van den Bosch MA, et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res. 2010;29:70.
15. Vente MA, de Wit TC, van den Bosch MA, et al. Holmium-166 poly(L-lactic acid) microsphere radioembolisation of the liver: technical aspects studied in a large animal model. Eur Radiol. 2010;20:862-869.
16. Prokop M, Galanski M, Schaefer-Prokop C. Spiral and Multislice Computed Tomography of the Body. Stuttgart, Germany: Thieme; 2003:421-425.
17. Bol GH, Kotte AN, van der Heide UA, Lagendijk JJ. Simultaneous multi-modality ROI delineation in clinical practice. Comput Methods Programs Biomed. 2009;96:133-140.
18. Li W, Zhang Z, Guo Y, Nicolai J, Reed A, Larson A. SPIO-labeled 90Y microspheres permit accurate quantification of macroscopic intra-hepatic biodistribution. Paper presented at: International Society for Magnetic Resonance in Medicine, 2013; Salt Lake City, Utah.
19. van de Maat GH, Seevinck PR, Elschot M, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol. 2013;23:827-835.
20. Bolch WE, Bouchet LG, Robertson JS, et al. MIRD pamphlet no. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med. 1999;40 (suppl):11S-36S.
21. Hendricks JS, McKinney GW, Waters LS, et al. MCNPX Extensions, Version 2.5.0. Los Alamos, CA: Los Alamos National Laboratory; 2005. Report LA-UR-05-2675.
22. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45: 228-247.
24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
25. Dhabuwala A, Lamerton P, Stubbs RS. Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT). BMC Nucl Med. 2005;5:7.
26. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.
27. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552-1563.
28. Gyves JW, Ziessman HA, Ensminger WD, et al. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J Nucl Med. 1984;25:972-977.
29. Ho S, Lau WY, Leung TW, et al. Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol. 1997;70:823-828.
30. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging. 2007;7:2-9.
31. Seppenwoolde JH, Bartels LW, van der Weide R, Nijsen JF, van het Schip AD, Bakker CJ. Fully MR-guided hepatic artery catheterization for selective drug delivery: a feasibility study in pigs. J Magn Reson Imaging. 2006;23:123-129.
32. Flamen P, Vanderlinden B, Delatte P, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53:6591-6603.
33. Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377-1385.
34. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2008;248:894-900.